Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Andrew Dorr"'
Autor:
William Martinez, James Paul, Victoria Shaffer, Emma Montgomery, Richelle Koopman, David Andrew Dorr, Aisha J Ghumman, LeAnn Michaels, Abigail Rolbiecki, Shannon Canfield, Blake Johnson, Melinda Lockwood, Parijat Ghosh, Emma Chase, Amy Yates, Michelle Bobo, Donald Casey, Jonathan R Soffer, Guilherme Del Fiol, Katherine Putnam, Matthew B Storer, Sheila Markwardt
Publikováno v:
BMJ Open, Vol 14, Iss 7 (2024)
Introduction Hypertension, the clinical condition of persistent high blood pressure (BP), is preventable yet remains a significant contributor to poor cardiovascular outcomes. Digital self-management support tools can increase patient self-care behav
Externí odkaz:
https://doaj.org/article/dcd3ddfdf07e415c9aeded6899f3ffa9
Autor:
Muralidhar Beeram, Judy S. Wang, Lida A. Mina, Pavani Chalasani, Rebecca A. Shatsky, Robert Wesolowski, Sara A. Hurvitz, Meghna S. Trivedi, Hyo S. Han, Amita Patnaik, My-my Huynh, Aarthi Jayanthan, Mary Rose Pambid, Lambert Yue, Gerrit Los, Sandra E. Dunn, Andrew Dorr
Publikováno v:
Cancer Research. 82:P5-17
Background: Durably effective therapeutic options remain elusive for metastatic triple negative breast cancer (mTNBC) patients. RSK is a novel target kinase for mTNBC, given its integral role in the MAPK/PDK-1 pathways. PMD-026, uniquely developed fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f6f4b1ffabbc6d6aabb9d6a6e35ddb0
https://doi.org/10.1158/1538-7445.sabcs21-p5-17-12
https://doi.org/10.1158/1538-7445.sabcs21-p5-17-12
Autor:
Timothy A. Yap, David J. Kwiatkowski, Jayesh Desai, Ibiayi Dagogo-Jack, Michael Millward, Hedy L. Kindler, Anthony W. Tolcher, Sophia Frentzas, Archie W. Thurston, Len Post, F Andrew Dorr
Publikováno v:
Cancer Research. 83:CT006-CT006
Background: Inactivation of the Hippo pathway is a common finding in MM and other cancers, leading to constitutive YAP activation, but has thus far been undruggable. NF2 encodes Merlin that activates Hippo kinase resulting in inactivation of YAP, whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c685fc4bcfe31012ade98134283f5a0a
https://doi.org/10.1158/1538-7445.am2023-ct006
https://doi.org/10.1158/1538-7445.am2023-ct006
Autor:
Jinjin Cai, Andrew Dorr, Laurie Rosenstein, Jim Labdon, Xiaojuan Li, Hang Zhou, Yanyuan Zhou, Wangjun He, Qiuping He, Xiaoyan Huang, Aparna R. Parikh, Marios Giannakis, Michael An
Publikováno v:
Cancer Research. 83:CT117-CT117
Background Inhibitors of the EGFR-RAS-RAF-MEK (MAPK) pathway have been successfully developed to treat cancers. However, many patients do not benefit from these inhibitors due to primary or acquired resistance. In colorectal cancer (CRC), resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6354c96df51688a014111aafdf2f75eb
https://doi.org/10.1158/1538-7445.am2023-ct117
https://doi.org/10.1158/1538-7445.am2023-ct117
Autor:
Judy S. Wang, Muralidhar Beeram, Pavani Chalasani, Lida Mina, Rebecca A. Shatsky, Sara Hurvitz, Meghna S. Trivedi, Robert Wesolowski, Hyo S. Han, Amita Patnaik, Shakeela Bahadur, My-my Huynh, Aarthi Jayanthan, Gerrit Los, Sandra E. Dunn, Andrew Dorr
Publikováno v:
Cancer Research. 83:P4-01
Background: Breast cancer (BC) is the most common malignancy in women and metastatic triple negative breast cancer (mTNBC) remains one of the most difficult to treat cancers with few targeted treatment options. RSK is recognized as a critical signali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86f4a4955f1917d426df057f63a82306
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-16
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-16
Autor:
Lida A. Mina, F. Andrew Dorr, My-my Huynh, Gerrit Los, Judy S. Wang, Pavani Chalasani, Aarthi Jayanthan, Murali Beeram, Amita Patnaik, Sandra E. Dunn, Mary Rose Pambid
Publikováno v:
Cancer Research. 81:PS11-33
Background: Metastatic breast cancer (mBC) remains an aggressive disease with limited durable treatment options; the worst prognosis among the breast cancer subtypes is typically seen in metastatic triple-negative breast cancer (mTNBC). Given that un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16343f734837c6b97dcccb09714c31c1
https://doi.org/10.1158/1538-7445.sabcs20-ps11-33
https://doi.org/10.1158/1538-7445.sabcs20-ps11-33
Publikováno v:
Expert Opinion on Investigational Drugs. 29:1199-1208
Triple negative breast cancer (TNBC) was once thought to be an insurmountable disease marked by a lack of targeted treatments. However, we are now witnessing the dawn of targeted therapies for TNBC in which progress has stemmed from an improved under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f1e74c1a6815bd220c110da1db53e23
https://doi.org/10.1080/13543784.2020.1818067
https://doi.org/10.1080/13543784.2020.1818067
Autor:
Rahul Raj Aggarwal, Jacqueline Vuky, David James VanderWeele, Matthew Rettig, Elisabeth I. Heath, Tomasz M. Beer, Jiaoti Huang, Nela Pawlowska, Ryan Sinit, Jill Abbey, Bin Liu, Marc Nasoff, Andrew Dorr, Eric Jay Small
Publikováno v:
Journal of Clinical Oncology. 40:3001-3001
3001 Background: FOR46, a fully human antibody (ab) conjugated to monomethyl auristatin E (MMAE), targets a tumor selective epitope of CD46, which is highly expressed in mCRPC and treatment-emergent small cell neuroendocrine cancer (t-SCNC). CD46 is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8799ed96afdfce74c107bb3046c8450f
https://doi.org/10.1200/jco.2022.40.16_suppl.3001
https://doi.org/10.1200/jco.2022.40.16_suppl.3001
Autor:
Jonathan L. Kaufman, Jeffrey A. Zonder, Sandy W. Wong, Philip H. Imus, Zachary Walker, Andrew Dorr, Jill Abbey, Ajai Imus, Marc Nasoff, Bin Liu, Mark A. Schroeder, Tomer M Mark, Thomas Martin, Daniel W. Sherbenou
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S164
Background Cluster of differentiation 46 (CD46) is highly expressed in multiple myeloma, especially in patients (pts) with gain of chromosome 1q and in the refractory setting. In vitro studies show upregulation and enhanced cytotoxicity upon treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::421bd7c1d815b159d6d9efd994738c23
https://doi.org/10.1016/s2152-2650(21)02352-1
https://doi.org/10.1016/s2152-2650(21)02352-1
Autor:
McHutchison, John G., Patel, Keyur, Pockros, Paul, Nyberg, Lisa, Pianko, Stephen, Yu, Rosie Z., Andrew Dorr, F., Kwoh, T. Jesse
Publikováno v:
In Journal of Hepatology January 2006 44(1):88-96